ArticleAnnals of nuclear medicine2025

Factors and predictors affecting late external dose rates and isolation period in patients after lutetium-177-labeled DOTA-Tyr3-octreotate treatment for neuroendocrine tumors.

Naoto Wakabayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.